| CDE ID | CDE Description | | * 421 | EDRN Participant ID (Go To: 423) |
| * 423 | EDRN Protocol ID (Go To: 422) |
| * 422 | EDRN Site ID (Go To: 929) |
| * 929 | EDRN Staff ID of the person who collected the data: (Go To: 1219) |
| * 1219 | Date of contact (MM/DD/YYYY): (Go To: 578) |
| * 578 | Age at specimen collection (Go To: 979) |
| * 979 | Date of digital rectal exam (DRE) (MM/DD/YYYY): (Go To: 976) |
| * 976 | Digital rectal exam results: (Go To: 2156) |
| | | Permissible Values (value): | Normal (1) |
|
| | | | Abnormal, clearly suspicious for cancer (6) (Go To: 2173) |
|
| | |
| 2173 | Amount of induration/nodularity on digital rectal exam (DRE), if not normal: (Go To: 2156) |
| | | Permissible Values (value): | Bilateral (5) |
|
| | | | Abnormal DRE but extent not specified (6) |
|
| | | | Left greater than right (7) |
|
| | | | Right greater than left (8) |
|
| * 2156 | Number of PSAs performed: (Go To: 1582) |
| * 1582 | Date of PSA: (Go To: 947) |
| * 947 | PSA (ng/ml) (Go To: 2502) |
| 2502 | PSA test used: (Go To: 4546) |
| | | Permissible Values (value): | Bayer Immuno-1 PSA Test (1) |
|
| | |
| | | | Roche Diagnostics Free PSA Test (4) |
|
| | | | Other, specify: (97) (Go To: 2503) |
|
| 2503 | PSA test used (Other, specify): (Go To: 4546) |
| * 4546 | Has the participant had a biomarker test performed? (Go To: 2495) |
| | | Permissible Values (value): | No (0) |
|
| | |
| | |
| * 3214 | Number of subform loops to record 2: (Go To: 3201) |
| | | Permissible Values (value): | 1 (1) |
|
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| * 3201 | Line number or identifier 2 (system-generated): (Go To: 4547) |
| * 4547 | Prostate biomarker test name: (Go To: 4548) |
| | | Permissible Values (value): | 4Kscore (1) |
|
| | |
| | |
| | | | Oncotype DX for Prostate Cancer (GPS) (4) |
|
| | |
| | |
| | | | Prostate Health Index (PHI) (7) |
|
| | |
| | |
| | |
| 4548 | Biomarker test name (Other, specify): (Go To: 4551) |
| * 4551 | Date of biomarker test (MM/DD/YYYY) (Go To: 4549) |
| * 4549 | Biomarker test result: (Go To: 4552) |
| 4552 | Biomarker test result 2: (Go To: 4553) |
| 4553 | Biomarker test result 3: (Go To: 3163) |
| 3163 | Loop-specific comments 2: (Go To: 2495) |
| * 2495 | Cancer diagnosis method: (Go To: 2499) |
| | | Permissible Values (value): | Diagnostic biopsy (1) (Go To: 1698) |
|
| | | | Suprapubic prostatectomy (3) (Go To: 2499) |
|
| | | | Transurethral resection of the prostate (TURP) (5) (Go To: 2499) |
|
| | | | Other, specify: (97) (Go To: 2496) |
|
| * 2496 | Cancer diagnosis method (Other, specify): (Go To: 3223) |
| 2499 | Number of specimens collected from secondary method: (Go To: 2498) |
| 2498 | Number of tissue specimens with cancer obtained from secondary method: (Go To: 2497) |
| 2497 | Per cent of cancer in tissue obtained from secondary method: (Go To: 2500) |
| 2500 | Primary Gleason grade obtained from secondary method: (Go To: 2501) |
| 2501 | Secondary Gleason grade obtained from secondary method. (Go To: 3223) |
| * 3223 | Date of procedure (MM/DD/YYYY): (Go To: 1698) |
| * 1698 | How many prostate biopsies have you previously had? (Go To: 5020) |
| * 5020 | Did participant have one or more negative biopsies prior to diagnostic biopsy? (Go To: 1097) |
| | | Permissible Values (value): | No (0) |
|
| | |
| | |
| 1097 | Comments (do not include any participant identifiers) (Go To: End of Form) |